TNFRSF18 and neoplasm: Another study demonstrates that anti-GITR treatment together with CD8+ cells in SCID recipient mice is sufficient to reject the tumor, while CD4+ transferred cells are not, although CD4+ cells play a central role in helping the functions of CD8+, NK and B cells [60].